Roivant Sciences Ltd. $ROIV Position Lifted by Danske Bank A S

Danske Bank A S grew its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 62,000.0% in the third quarter, Holdings Channel.com reports. The firm owned 186,300 shares of the company’s stock after acquiring an additional 186,000 shares during the quarter. Danske Bank A S’s holdings in Roivant Sciences were worth $6,813,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Roivant Sciences by 179.0% during the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after buying an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. purchased a new stake in Roivant Sciences in the 1st quarter valued at $45,066,000. Assenagon Asset Management S.A. grew its holdings in Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after buying an additional 1,286,464 shares in the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Roivant Sciences by 64.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after acquiring an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Roivant Sciences in the 3rd quarter worth $35,624,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $38.73 on Thursday. The firm has a 50 day simple moving average of $37.26 and a 200-day simple moving average of $32.50. Roivant Sciences Ltd. has a one year low of $19.96 and a one year high of $42.50.

Insider Buying and Selling

In other Roivant Sciences news, CFO Richard Pulik sold 175,000 shares of the stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $41.85, for a total value of $7,323,750.00. Following the sale, the chief financial officer owned 222,046 shares of the company’s stock, valued at $9,292,625.10. This trade represents a 44.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Gold sold 602,021 shares of Roivant Sciences stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $38.24, for a total value of $23,021,283.04. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,037,149 shares of company stock valued at $115,829,136 in the last three months. 8.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Guggenheim upped their price objective on shares of Roivant Sciences from $46.00 to $48.00 and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group lifted their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.82.

Get Our Latest Research Report on ROIV

Roivant Sciences Profile

(Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Featured Stories

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.